NCT02258607: Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase |
|
|
| Terminated | 1b | 21 | US | Momelotinib (MMB), GS-0387, CYT387, Trametinib | Sierra Oncology, Inc. | Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer | 07/16 | 02/17 | | |
NCT01938456: Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer |
|
|
| Withdrawn | 1 | 0 | Japan | Trametinib, Docetaxel, Filgrastim | GlaxoSmithKline | Lung Cancer, Non-Small Cell | 07/14 | 07/14 | | |
